Neuronal surface antibody syndromes(NSAS)encompass a variety of disorders associated with“neuronal surface antibodies”.These share clinical and neuroradiological features that pose challenges related to their recogn...Neuronal surface antibody syndromes(NSAS)encompass a variety of disorders associated with“neuronal surface antibodies”.These share clinical and neuroradiological features that pose challenges related to their recognition and treatment.Recent epidemiological studies show a clear predominance for the glutamate-N-methyl-D-aspartate receptor encephalitis in both adults and pediatric population.Despite this,the overall NSAS’s incidence remains underestimated,and diagnosis persists to be not always easy to achieve.Based on current literature data,in this paper the authors propose a diagnostic pathway to approach and treat pediatric NSAS.An autoimmune etiology can be suggested through the integration of clinical,immunological,electrophysiological and neuroradiological data.On that basis,a target treatment can be started,consisting of corticosteroids and intravenous immunoglobulin or plasma exchange as a first-line immunotherapy,followed by second-line drugs including rituximab,cyclophosphamide or mycophenolate mophetil,if the case.In children a prompt diagnosis and a targeted treatment may lead to a better clinical outcome.Nevertheless further studies are required to assess the need of more tailored treatments according to long-term outcome findings and prognostic factors in different NSAS.展开更多
文摘Neuronal surface antibody syndromes(NSAS)encompass a variety of disorders associated with“neuronal surface antibodies”.These share clinical and neuroradiological features that pose challenges related to their recognition and treatment.Recent epidemiological studies show a clear predominance for the glutamate-N-methyl-D-aspartate receptor encephalitis in both adults and pediatric population.Despite this,the overall NSAS’s incidence remains underestimated,and diagnosis persists to be not always easy to achieve.Based on current literature data,in this paper the authors propose a diagnostic pathway to approach and treat pediatric NSAS.An autoimmune etiology can be suggested through the integration of clinical,immunological,electrophysiological and neuroradiological data.On that basis,a target treatment can be started,consisting of corticosteroids and intravenous immunoglobulin or plasma exchange as a first-line immunotherapy,followed by second-line drugs including rituximab,cyclophosphamide or mycophenolate mophetil,if the case.In children a prompt diagnosis and a targeted treatment may lead to a better clinical outcome.Nevertheless further studies are required to assess the need of more tailored treatments according to long-term outcome findings and prognostic factors in different NSAS.
